• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by STERIS plc (Ireland)

    7/3/25 4:32:12 PM ET
    $STE
    Industrial Specialties
    Health Care
    Get the next $STE alert in real time by email
    DEFA14A 1 d840353ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    PROXY STATEMENT Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.  )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to § 240.14a-12

    STERIS plc

    (Name of Registrant as Specified in its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(l) and 0-11.

     

     
     


    LOGO

    STERIS plc

    70 Sir John Rogerson’s Quay

    Dublin 2, D02 R296, Ireland

    SUPPLEMENT TO PROXY STATEMENT

    FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS

    TO BE HELD JULY 31, 2025

    This supplement (this “Supplement”) supplements the definitive proxy statement on Schedule 14A (as supplemented, the “Proxy Statement”) filed by STERIS plc (the “Company”) with the Securities and Exchange Commission (the “SEC”) on June 12, 2025 in connection with the Company’s 2025 Annual General Meeting of Shareholders (the “Annual Meeting”), to be held on July 31, 2025 at 9:00 a.m., Irish Standard Time.

    This Supplement is being filed with the SEC and is being made available to the shareholders of the Company on or about July 3, 2025. Except as described in this Supplement, the information provided in the Proxy Statement continues to apply. To the extent the information in this Supplement differs from or updates information in the Proxy Statement, our shareholders should rely on the information contained in this Supplement.

    As described in our Current Report on Form 8-K filed with the SEC on July 3, 2025, Dr. Richard M. Steeves notified the Company on July 1, 2025 that he will retire from the Board of Directors (the “Board”) on the date of the Annual Meeting to be held on July 31, 2025. Due to his retirement, Dr. Steeves’ name has been withdrawn from nomination for re-election to the Board at the Annual Meeting. Dr. Steeves’ decision to retire was not the result of any disagreement with the Company on any matters related to the Company’s strategy, operations, policies or practices.

    The Board has determined not to fill Dr. Steeves’ vacancy or appoint a successor nominee for election at the Annual Meeting. All nominees, other than Dr. Steeves due to his retirement as a director, named in the Proxy Statement continue to stand for election at the Annual Meeting, and the form of proxy card included with the Proxy Statement remains valid. However, any votes that are submitted for Dr. Steeves will be disregarded. If you have already voted your proxy, you do not need to take any action unless you desire to change your vote by submitting a new proxy, and your shares will be voted as specified therein, other than any votes with respect to Dr. Steeves. If you have not yet voted your proxy, please complete and return the proxy, disregarding Dr. Steeves’ name as a director nominee.

    None of the other agenda items and proposals presented in the Proxy Statement are modified by this Supplement.

    THE PROXY STATEMENT CONTAINS IMPORTANT ADDITIONAL INFORMATION. THIS

    SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT.

    EXCEPT AS SPECIFICALLY SUPPLEMENTED BY THE INFORMATION CONTAINED HEREIN,

    THIS SUPPLEMENT DOES NOT MODIFY ANY OTHER INFORMATION SET FORTH IN THE PROXY

    STATEMENT OR THE PROXY CARD AND THEY CONTINUE TO BE IN FULL FORCE AND EFFECT

    AS ORIGINALLY FILED.

    Please note that any proxy card that you received has not changed and may still be used to vote your shares in connection with the Annual Meeting, except as provided above. If you have already voted your proxy, you do not need to take any further action. Information on how to vote your shares and how to change your vote or revoke your proxy is contained in the Proxy Statement. Whether or not you plan to attend the Annual Meeting, the Company urges you to please cast your vote as soon as possible by using one of the methods described in the Proxy Statement.

    Get the next $STE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STE

    DatePrice TargetRatingAnalyst
    7/15/2025$276.00Equal-Weight → Overweight
    Morgan Stanley
    5/29/2025$263.00Hold
    Jefferies
    10/24/2024$230.00 → $260.00Neutral → Overweight
    Piper Sandler
    2/6/2024$253.00Overweight
    KeyBanc Capital Markets
    5/30/2023$206.00Equal-Weight
    Morgan Stanley
    4/14/2023$215.00 → $197.00Overweight → Neutral
    Piper Sandler
    9/23/2022Buy → Hold
    Needham
    7/14/2022$240.00Overweight
    Piper Sandler
    More analyst ratings

    $STE
    SEC Filings

    View All

    SEC Form 10-Q filed by STERIS plc (Ireland)

    10-Q - STERIS plc (0001757898) (Filer)

    2/6/26 4:04:07 PM ET
    $STE
    Industrial Specialties
    Health Care

    STERIS plc (Ireland) filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - STERIS plc (0001757898) (Filer)

    2/4/26 4:32:07 PM ET
    $STE
    Industrial Specialties
    Health Care

    SEC Form 144 filed by STERIS plc (Ireland)

    144 - STERIS plc (0001757898) (Subject)

    11/18/25 4:46:18 PM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Steris upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Steris from Equal-Weight to Overweight and set a new price target of $276.00

    7/15/25 8:30:16 AM ET
    $STE
    Industrial Specialties
    Health Care

    Jefferies initiated coverage on Steris with a new price target

    Jefferies initiated coverage of Steris with a rating of Hold and set a new price target of $263.00

    5/29/25 8:18:41 AM ET
    $STE
    Industrial Specialties
    Health Care

    Steris upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Steris from Neutral to Overweight and set a new price target of $260.00 from $230.00 previously

    10/24/24 6:28:31 AM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP, Chf. Comp. & Quality Offc. Mcgowan Lindsey was granted 798 units of Ordinary Shares, increasing direct ownership by 19% to 5,028 units (SEC Form 4)

    4 - STERIS plc (0001757898) (Issuer)

    1/6/26 4:32:31 PM ET
    $STE
    Industrial Specialties
    Health Care

    New insider Mcgowan Lindsey claimed ownership of 4,478 units of Ordinary Shares (SEC Form 3)

    3 - STERIS plc (0001757898) (Issuer)

    1/6/26 4:31:17 PM ET
    $STE
    Industrial Specialties
    Health Care

    Sr. VP and GM, Life Sciences Madsen Julia exercised 5,008 units of Ordinary Shares at a strike of $128.22 and sold $1,312,096 worth of Ordinary Shares (5,008 units at $262.00) (SEC Form 4)

    4 - STERIS plc (0001757898) (Issuer)

    11/25/25 4:39:27 PM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    STERIS Announces Financial Results for Fiscal 2026 Third Quarter

    Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.96; adjusted EPS increased to $2.53Fiscal 2026 outlook maintained DUBLIN, IRELAND, Feb. 04, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2026 third quarter ended December 31, 2025. Total revenue from continuing operations for the third quarter of fiscal 2026 increased 9% to $1.5 billion compared with $1.4 billion in the third quarter of fiscal 2025. Constant currency organic revenue growth from continuing operations for the third quarter was 8%. "We are pl

    2/4/26 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    STERIS Announces Dividend of $0.63 per share

    DUBLIN, IRELAND, Jan. 28, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly dividend of $0.63 per share. The dividend is payable on March 19, 2026, to shareholders of record at the close of business on February 17, 2026.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and serv

    1/28/26 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    STERIS to Host a Conference Call for Fiscal 2026 Third Quarter Results on February 5, 2026

    DUBLIN, IRELAND, Jan. 21, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2026 third quarter results at 9:00 a.m. ET on February 5, 2026. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on February 4, 2026. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on February 5, 2026, either

    1/21/26 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Financials

    Live finance-specific insights

    View All

    STERIS Announces Financial Results for Fiscal 2026 Third Quarter

    Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.96; adjusted EPS increased to $2.53Fiscal 2026 outlook maintained DUBLIN, IRELAND, Feb. 04, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2026 third quarter ended December 31, 2025. Total revenue from continuing operations for the third quarter of fiscal 2026 increased 9% to $1.5 billion compared with $1.4 billion in the third quarter of fiscal 2025. Constant currency organic revenue growth from continuing operations for the third quarter was 8%. "We are pl

    2/4/26 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    STERIS Announces Dividend of $0.63 per share

    DUBLIN, IRELAND, Jan. 28, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly dividend of $0.63 per share. The dividend is payable on March 19, 2026, to shareholders of record at the close of business on February 17, 2026.   Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and serv

    1/28/26 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    STERIS to Host a Conference Call for Fiscal 2026 Third Quarter Results on February 5, 2026

    DUBLIN, IRELAND, Jan. 21, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2026 third quarter results at 9:00 a.m. ET on February 5, 2026. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on February 4, 2026. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on February 5, 2026, either

    1/21/26 4:30:00 PM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

    SC 13G/A - STERIS plc (0001757898) (Subject)

    2/13/24 5:14:05 PM ET
    $STE
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

    SC 13G/A - STERIS plc (0001757898) (Subject)

    2/9/24 11:49:03 AM ET
    $STE
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by STERIS plc (Ireland) (Amendment)

    SC 13G/A - STERIS plc (0001757898) (Subject)

    2/9/24 11:32:52 AM ET
    $STE
    Industrial Specialties
    Health Care

    $STE
    Leadership Updates

    Live Leadership Updates

    View All

    METTLER TOLEDO Announces Michael J. Tokich to Join Board of Directors

    Mettler-Toledo International Inc. (NYSE:MTD) announced today that Michael J. Tokich has been appointed to its Board of Directors, effective February 5, 2026. Mr. Tokich served for over 17 years as Senior Vice President and Chief Financial Officer ("CFO") at STERIS plc (NYSE:STE), a leading global healthcare and life science provider of products and services, prior to recently transitioning to the role of Senior Financial Advisor at STERIS. Mr. Tokich joined STERIS in 2000 and held various senior financial roles prior to his appointment as CFO in 2008. Roland Diggelmann, Chair of the Board, stated, "Mike is a highly accomplished executive who brings nearly two decades of U.S. public comp

    1/20/26 4:30:00 PM ET
    $MTD
    $STE
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Industrial Specialties
    Health Care

    CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors

    SAN RAMON, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today that the Company's Board of Directors (the "Board") has appointed Walter (Walt) M Rosebrough, Jr. as an independent director, effective as of January 3, 2026. In connection with this appointment, the Company also has entered into a cooperation agreement (the "Cooperation Agreement") with Browning West, LP. ("Browning West"). Mr. Rosebrough will join the Board's Corporate Governance & Nominating Committee. The Board has also agreed that, by the end of 2026, it shall provide due and serious consideration for Mr. Rosebrough to be appointed Chair of the Board. In

    12/23/25 8:00:00 AM ET
    $COO
    $STE
    $VREX
    Ophthalmic Goods
    Health Care
    Industrial Specialties
    Industrial Machinery/Components

    STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors

    DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. "We are pleased to welcome Dr. Alegria to our Board," said Mohsen Sohi, Chairman of STERIS. "She brings over three decades of experience in the biopharmaceuticals industry to our Board and will be a valuable addition." Dr. Alegria is the Founder and Chief Executive Officer of APIE Therapeutics, where she leads a team focused on the development of therapeutic drugs to treat chronic and debilitating diseases. Prior to APIE, Dr. Alegria was President and Senior Executive Advisor at Catal

    5/3/23 4:30:00 PM ET
    $CDMO
    $STE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties